waynakyo
Experienced Member
- Reaction score
- 464
Red flags around this one, but posting it nevertheless. lol about the "results" line. Study made by the doctor who is selling the product.
Abstract
Introduction: Androgenetic Alopecia (Androgenetic Alopecia) with its precursor Miniaturization of Anagen phase (MA), and Telogen Effluvium (Telogen Effluvium) represent non-scarring hair loss diseases which causes moderate to severe aesthetic and psychologic discomfort in affected people. Several therapeutic approaches have been tested through the latest decades, with different degree of success.Objective: To analyse the efficacy and outcome of an innovative therapeutic protocol, named TRICHOBIOLIGHT®, a combination of active principles conveyed by mesotherapy directly on the scalp with a subsequent photobiostimulation session with LED light (630nm).
Methods: One-hundred-seven patients (49 women, 58 men, mean age 45 year-old) with clinical and trichoscopic diagnosis of MA, Androgenetic Alopecia and Telogen Effluvium have been enrolled at Skin Center of L'Aquila, Avezzano and Pescara (Italy) and all have been treated with the TRICHOBIOLIGHT® protocol. Four patients dropped out at the beginning of the study: two patients because of an histological diagnosis of scarring alopecia and lichen scleroatrophicus, respectively, and two patients dropped out because of adverse reaction to the treatment (persistent itching, redness and scales).
Results: Excellent to good outcome have been reached in the 82,5% of patients (85/103), 9 patients (8,7%) reached a sufficient result whilst 7 patients (6,8%) partially respond to the treatment. Two patients (2%) did not respond at all.
Conclusions: TRICHOBIOLIGHT® is a promising protocol, working through the combined action of the active principles and the photobiostimulation, that lead to a strengthening and thickening of the residual hair, giving an optical thickening effect that provides high quality aesthetic results and, consequently, appreciable psychological results. This article is protected by copyright. All rights reserved.